Trial Search Results

Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy

This registry will remain open for approximately 5 years (4 years of enrollment + 1 year of follow up). Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Gilead Sciences

Stanford Investigator(s):


  • Drug: Anti-HBV nucleoside/nucleotide therapy


Key Inclusion Criteria:

   - Estimated glomerular filtration rate (Cockcroft-Gault method)using actual body weight
   of ≥ 50 mL/min at time of entry into registry

   - Negative serologies for HIV, hepatitis C virus (HCV), and/or hepatitis D virus (HDV)

   - No history of solid organ or bone marrow transplant

   - Currently receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy
   within 6 months of inclusion into registry

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Mindie Nguyen
Not Recruiting